Jon Amund Eriksen

2.4k citations

32 papers · 2.0k indexed · h-index 22

Co-authors: Gustav Gaudernack Mona Møller Marianne Klemp Erik Thorsby Trond Buanes Tobias Gedde‐Dahl Ivar P. Gladhaug Ingvil Sæterdal
Topics: Immunotherapy and Immune Responses (16 papers)Cancer Immunotherapy and Biomarkers (12 papers)Monoclonal and Polyclonal Antibodies Research (6 papers)
Cited by: Immunology Oncology Energy Engineering and Power Technology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: Norway United Kingdom Germany

In The Last Decade

Jon Amund Eriksen

30 papers receiving 1.9k citations

Peers

Countries citing papers authored by Jon Amund Eriksen

Since Specialization

Citations

This map shows the geographic impact of Jon Amund Eriksen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Amund Eriksen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Amund Eriksen more than expected).

Fields of papers citing papers by Jon Amund Eriksen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Amund Eriksen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Amund Eriksen. The network helps show where Jon Amund Eriksen may publish in the future.

Co-authorship network of co-authors of Jon Amund Eriksen

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Amund Eriksen. A scholar is included among the top collaborators of Jon Amund Eriksen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Amund Eriksen. Jon Amund Eriksen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study 2025 ·Cancer Immunology Immunotherapy ·Else-Marit Inderberg-Suso,(unknown),(unknown),Sarah Arbe‐Barnes,(unknown),(unknown),(unknown),Jon Amund Eriksen,(unknown)	0
2	A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer 2024 ·Heliyon ·(unknown),(unknown),Robert G. Ramsay,Catherine Mitchell,Shienny Sampurno,Toàn Pham,Joseph C. Kong,Stephen Q. Wong,Alexander G. Heriot,Sanjeev Deva,Matthew Burge,(unknown),Anne‐Sophie W. Møller,Łukasz Kuryk,Jon Amund Eriksen,Magnus Jäderberg,John Zalcberg,Michael Michael	2
3	HYDRIDE4MOBILITY: An EU HORIZON 2020 project on hydrogen powered fuel cell utility vehicles using metal hydrides in hydrogen storage and refuelling systems 2021 ·International Journal of Hydrogen Energy ·V.A. Yartys,Mykhaylo Lototskyy,Vladimir Linkov,Sivakumar Pasupathi,Moegamat Wafeeq Davids,Ivan Tolj,Gojmir Radica,R.V. Denys,Jon Amund Eriksen,K. Taube,José M. Bellosta von Colbe,Giovanni Capurso,Martin Dornheim,Fahmida Smith,(unknown),Dana Swanepoel,Suwarno Suwarno	50
4	TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial 2020 ·British Journal of Cancer ·Daniel H. Palmer,Juan W. Valle,Yuk Ting,Olusola Olusesan Faluyi,John P. Neoptolemos,(unknown),(unknown),Jon Amund Eriksen,(unknown),Anne-Kirsti Aksnes,Robert C. Miller,Svein Dueland	49
5	An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer 2017 ·Annals of Oncology ·Jon Amund Eriksen,I P Gladhaug,Arne R. Rosseland,(unknown),Trond Buanes	5
6	Vaccination of patients with cutaneous melanoma with telomerase-specific peptides 2011 ·Cancer Immunology Immunotherapy ·Robert E. Hunger,Kristin Lang,(unknown),Sissel Trachsel,Mona Møller,Jon Amund Eriksen,(unknown),Lasse R. Braathen,Gustav Gaudernack	47
7	Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras 2010 ·International Journal of Cancer ·(unknown),Marianne Klemp,Ivar P. Gladhaug,Mona Møller,Jon Amund Eriksen,Gustav Gaudernack,Trond Buanes	137
8	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study 2006 ·British Journal of Cancer ·Stephan Bernhardt,(unknown),Dagmar S. Trachsel,Mona Møller,Jon Amund Eriksen,(unknown),Trond Buanes,Gustav Gaudernack	238
9	Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer 2006 ·Cancer Immunology Immunotherapy ·Paal Brunsvig,Steinar Aamdal,Marianne Klemp,Gunnar Kvalheim,(unknown),(unknown),(unknown),Sissel Trachsel,Mona Møller,Jon Amund Eriksen,Gustav Gaudernack	196
10	Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM‐CSF as adjuvant 2001 ·Experimental Dermatology ·Robert E. Hunger,C.U. Brand,Michael Streit,Jon Amund Eriksen,(unknown),Ingvil Sæterdal,Lasse R. Braathen,Gustav Gaudernack	33
11	A TGFβRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cells 2001 ·Cancer Immunology Immunotherapy ·Ingvil Sæterdal,Marianne Klemp,Per thor Straten,Jon Amund Eriksen,Gustav Gaudernack	61
12	Selection of a cyclic nonapeptide inhibitor to α-chymotrypsin using a phage display peptide library 1997 ·Molecular Diversity ·(unknown),Christer Lindbladh,Jon Amund Eriksen,Klaus Mosbach	22
13	Identification of a putative motif for binding of peptides to HLA-DQ2 1996 ·International Immunology ·(unknown),Frode Vartdal,Jon Amund Eriksen,Erik Thorsby,Ludvig M. Sollid	73
14	Selection of peptides with surface affinity for α-chymotrypsin using a phage display library 1995 ·Journal of Chromatography A ·(unknown),Christer Lindbladh,Staffan Birnbaum,(unknown),Jon Amund Eriksen,Klaus Mosbach	15
15	Binding of peptides to HLA-DQ molecules: peptide binding properties of the disease-associated HLA-DQ(α1^0501, β1^0201) molecule 1994 ·International Immunology ·(unknown),Søren Buus,(unknown),(unknown),Jon Amund Eriksen,Erik Thorsby,(unknown)	40
16	p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4⁺ and CD8⁺ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp) 1994 ·International Journal of Cancer ·(unknown),Tobias Gedde‐Dahl,Jarle Breivik,Jon Amund Eriksen,Anne Spurkland,Erik Thorsby,Gustav Gaudernack	70
17	Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cells 1993 ·European Journal of Immunology ·(unknown),Tobias Gedde‐Dahl,(unknown),Jon Amund Eriksen,(unknown),Gustav Gaudernack	50
18	T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restriction 1993 ·European Journal of Immunology ·Tobias Gedde‐Dahl,(unknown),Jon Amund Eriksen,Erik Thorsby,Gustav Gaudernack	46
19	Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gin → Leu61) 1992 ·International Immunology ·Tobias Gedde‐Dahl,Anne Spurkland,Jon Amund Eriksen,Erik Thorsby,Gustav Gaudernack	53
20	T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides 1992 ·Human Immunology ·Tobias Gedde‐Dahl,Jon Amund Eriksen,Erik Thorsby,Gustav Gaudernack	51

About Jon Amund Eriksen

Jon Amund Eriksen is a scholar working on Immunology, Oncology and Biotechnology, having authored 32 papers that have together received 2.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (16 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). The work is most often cited by research in Immunology (965 citations), Oncology (979 citations) and Energy Engineering and Power Technology (99 citations). Jon Amund Eriksen has collaborated with scholars based in Norway, United Kingdom and Germany. Frequent co-authors include Gustav Gaudernack, Mona Møller, Marianne Klemp, Erik Thorsby, Trond Buanes, Tobias Gedde‐Dahl, Ivar P. Gladhaug, Ingvil Sæterdal, Stephan Bernhardt and Dagmar S. Trachsel. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact